|
|
Blood, 1 June 2005, Vol. 105, No. 11, pp. 4484-4491.
Prepublished online as a Blood First Edition Paper on February 3, 2005; DOI 10.1182/blood-2004-07-2713.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival
Azra J. Alvi,
Belinda Austen,
Victoria J. Weston,
Christopher Fegan,
David MacCallum,
Athos Gianella-Borradori,
David P. Lane,
Mike Hubank,
Judith E. Powell,
Wenbin Wei,
A. Malcolm R. Taylor,
Paul A. H. Moss, and
Tatjana Stankovic
From the Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom; the Department of Haematology, Birmingham Heartlands Hospital, Birmingham, United Kingdom; Cyclacel, Dundee, Scotland, United Kingdom; the Department of Molecular Haematology, Institute of Child Health, University College London, United Kingdom; and the Department of Public Health and Epidemiology, University of Birmingham, United Kingdom.
B-cell chronic lymphocytic leukemia (B-CLL) is a clinically variable disease where mutations in DNA damage response genes ATM or TP53 affect the response to standard therapeutic agents. The in vitro cytotoxicity of a novel cyclin-dependent kinase inhibitor, CYC202, was evaluated in 26 B-CLLs, 11 with mutations in either the ATM or TP53 genes, and compared with that induced by ionizing radiation and fludarabine. CYC202 induced apoptosis within 24 hours of treatment in all 26 analyzed tumor samples independently of ATM and TP53 gene status, whereas 6 of 26 B-CLLs, mostly ATM mutant, showed marked in vitro resistance to fludarabine-induced apoptosis. Compared with B-CLLs, normal T and B lymphocytes treated with CYC202 displayed reduced and delayed apoptosis. Using global gene expression profiling, we found that CYC202 caused a significant down-regulation of genes involved in regulation of transcription, translation, survival, and DNA repair. Furthermore, induction of apoptosis by CYC202 was preceded by inhibition of RNA polymerase II phosphorylation, leading to down-regulation of several prosurvival proteins. We conclude that CYC202 is a potent inducer of apoptosis in B-CLL regardless of the functional status of the p53 pathway, and may be considered as a therapeutic agent to improve the outcome of resistant B-CLL tumors.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. B.Y. Hui, S. Yue, W. Shi, N. M. Alajez, E. Ito, S. R. Green, S. Frame, B. O'Sullivan, and F.-F. Liu
Therapeutic Efficacy of Seliciclib in Combination with Ionizing Radiation for Human Nasopharyngeal Carcinoma
Clin. Cancer Res.,
June 1, 2009;
15(11):
3716 - 3724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chen, W. G. Wierda, S. Chubb, R. E. Hawtin, J. A. Fox, M. J. Keating, V. Gandhi, and W. Plunkett
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
Blood,
May 7, 2009;
113(19):
4637 - 4645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-S. Hsieh, R. Soo, B.-K. Peh, T. Loh, D. Dong, D. Soh, L.-S. Wong, S. Green, J. Chiao, C.-Y. Cui, et al.
Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer
Clin. Cancer Res.,
February 15, 2009;
15(4):
1435 - 1442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Najjar, P. O. Schischmanoff, F. Baran-Marszak, P.-A. Deglesne, I. Youlyouz-Marfak, M. Pampin, J. Feuillard, G. W. Bornkamm, M. K. Chelbi-Alix, and R. Fagard
Novel function of STAT1{beta} in B cells: induction of cell death by a mechanism different from that of STAT1{alpha}
J. Leukoc. Biol.,
December 1, 2008;
84(6):
1604 - 1612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Garrofe-Ochoa, R. M. Melero-Fernandez de Mera, F. J. Fernandez-Gomez, J. Ribas, J. Jordan, and J. Boix
BAX and BAK proteins are required for cyclin-dependent kinase inhibitory drugs to cause apoptosis
Mol. Cancer Ther.,
December 1, 2008;
7(12):
3800 - 3806.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Austen, A. Skowronska, C. Baker, J. E. Powell, A. Gardiner, D. Oscier, A. Majid, M. Dyer, R. Siebert, A. M. Taylor, et al.
Mutation Status of the Residual ATM Allele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q Deletion
J. Clin. Oncol.,
December 1, 2007;
25(34):
5448 - 5457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Weingrill, A. Wolfler, D. Strunk, W. Linkesch, H. Sill, and P. M. Liebmann
Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status
Haematologica,
September 1, 2007;
92(9):
1286 - 1288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mody, N. Dharker, M. Bloomston, P.-S. Wang, F.-S. Chou, T. S Glickman, T. McCaffrey, Z. Yang, A. Pumfery, D. Lee, et al.
Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-{alpha}, CH11 and CYC202
Endocr. Relat. Cancer,
June 1, 2007;
14(2):
305 - 315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Czabotar, E. F. Lee, M. F. van Delft, C. L. Day, B. J. Smith, D. C. S. Huang, W. D. Fairlie, M. G. Hinds, and P. M. Colman
Structural insights into the degradation of Mcl-1 induced by BH3 domains
PNAS,
April 10, 2007;
104(15):
6217 - 6222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Smit, D. Y.H. Hallaert, R. Spijker, B. de Goeij, A. Jaspers, A. P. Kater, M. H.J. van Oers, C. J.M. van Noesel, and E. Eldering
Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity
Blood,
February 15, 2007;
109(4):
1660 - 1668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chen, Y. Dai, H. Harada, P. Dent, and S. Grant
Mcl-1 Down-regulation Potentiates ABT-737 Lethality by Cooperatively Inducing Bak Activation and Bax Translocation
Cancer Res.,
January 15, 2007;
67(2):
782 - 791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Iurisci, E. Filipski, J. Reinhardt, S. Bach, A. Gianella-Borradori, S. Iacobelli, L. Meijer, and F. Levi
Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor.
Cancer Res.,
November 15, 2006;
66(22):
10720 - 10728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. I. Shapiro
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
J. Clin. Oncol.,
April 10, 2006;
24(11):
1770 - 1783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Rosato, J. A. Almenara, S. C. Maggio, P. Atadja, R. Craig, J. Vrana, P. Dent, and S. Grant
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells
Mol. Cancer Ther.,
November 1, 2005;
4(11):
1772 - 1785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Austen, J. E. Powell, A. Alvi, I. Edwards, L. Hooper, J. Starczynski, A. M. R. Taylor, C. Fegan, P. Moss, and T. Stankovic
Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL
Blood,
November 1, 2005;
106(9):
3175 - 3182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rahmani, E. M. Davis, C. Bauer, P. Dent, and S. Grant
Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation
J. Biol. Chem.,
October 21, 2005;
280(42):
35217 - 35227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. Tirado, S. Mateo-Lozano, and V. Notario
Roscovitine Is an Effective Inducer of Apoptosis of Ewing's Sarcoma Family Tumor Cells In vitro and In vivo
Cancer Res.,
October 15, 2005;
65(20):
9320 - 9327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chen, M. J. Keating, V. Gandhi, and W. Plunkett
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
Blood,
October 1, 2005;
106(7):
2513 - 2519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.P. LANE
Exploiting the p53 Pathway for the Diagnosis and Therapy of Human Cancer
Cold Spring Harb Symp Quant Biol,
January 1, 2005;
70(0):
489 - 497.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. WORKMAN
Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics
Cold Spring Harb Symp Quant Biol,
January 1, 2005;
70(0):
499 - 515.
[Abstract]
[PDF]
|
|
|
|
|
